Loading...
•
Mar 31, 2023
ORIC Pharmaceuticals Q1 2023 Earnings Report
ORIC Pharmaceuticals reported financial results and operational updates for Q1 2023.
Key Takeaways
ORIC Pharmaceuticals reported cash and investments of $208.9 million, expected to fund the operating plan into the first half of 2025. The company is advancing its novel oncology pipeline, with initial Phase 1b data expected in the second half of 2023 for three ongoing clinical trials.
Initial Phase 1b data for ORIC-533 in multiple myeloma is expected in the second half of 2023.
Initial Phase 1b data for ORIC-114 in EGFR/HER2-mutated cancers is expected in the second half of 2023.
Initial Phase 1b data for ORIC-944 in prostate cancer is expected in the second half of 2023.
Preclinical data for ORIC-944 and PLK4 program were presented at the 2023 AACR Annual Meeting.
Forward Guidance
ORIC Pharmaceuticals expects the cash and investments of $208.9 million as of March 31, 2023 will be sufficient to fund its operating plan into the first half of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...